Isabelle J. Pouliquen

Stockley Park
Uxbridge, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Development of Pediatric Dosing for Mepolizumab in Severe Asthma Based on Extrapolation of Data From Adult Patients and a Phase II Open-Label Pediatric Trial.

Development of Pediatric Dosing for Mepolizumab in Severe Asthma Based on Extrapolation of Data From Adult Patients and a Phase II Open-Label Pediatric Trial.

Journal: Journal of clinical pharmacology

Published: August 22, 2025

Straight to Phase III: Model-Informed Approach Speeds Depemokimab Clinical Development in Interleukin-5-Driven Diseases.

Straight to Phase III: Model-Informed Approach Speeds Depemokimab Clinical Development in Interleukin-5-Driven Diseases.

Journal: Clinical pharmacology and therapeutics

Published: July 04, 2025

Phase 1, randomized trials of MEDI1341: cerebrospinal fluid free α-synuclein lowered by >50.

Phase 1, randomized trials of MEDI1341: cerebrospinal fluid free α-synuclein lowered by >50.

Journal: Brain communications

Published: December 03, 2024

A Phase 1 study of the long-acting anti-IL-5 monoclonal antibody GSK3511294 in patients with asthma.

A Phase 1 study of the long-acting anti-IL-5 monoclonal antibody GSK3511294 in patients with asthma.

Journal: British journal of clinical pharmacology

Published: March 30, 2021

Justification of the Subcutaneous Mepolizumab Dose of 300 mg in Eosinophilic Granulomatosis With Polyangiitis and Hypereosinophilic Syndrome.

Justification of the Subcutaneous Mepolizumab Dose of 300 mg in Eosinophilic Granulomatosis With Polyangiitis and Hypereosinophilic Syndrome.

Journal: Clinical therapeutics

Published: February 19, 2021

Assessing efficacy in important subgroups in confirmatory trials: An example using Bayesian dynamic borrowing.

Assessing efficacy in important subgroups in confirmatory trials: An example using Bayesian dynamic borrowing.

Journal: Pharmaceutical statistics

Published: November 14, 2019

Usability of mepolizumab single-use prefilled autoinjector for patient self-administration.

Usability of mepolizumab single-use prefilled autoinjector for patient self-administration.

Journal: The Journal of asthma : official journal of the Association for the Care of Asthma

Published: June 29, 2019

Efficacy and safety of mepolizumab administered subcutaneously for moderate to severe atopic dermatitis.

Efficacy and safety of mepolizumab administered subcutaneously for moderate to severe atopic dermatitis.

Journal: Allergy

Published: April 26, 2019

Usability of mepolizumab single-use prefilled syringe for patient self-administration.

Usability of mepolizumab single-use prefilled syringe for patient self-administration.

Journal: The Journal of asthma : official journal of the Association for the Care of Asthma

Published: April 25, 2019

The Pharmacokinetics and Relative Bioavailability of Mepolizumab 100 mg Liquid Formulation Administered Subcutaneously to Healthy Participants: A Randomized Trial.

The Pharmacokinetics and Relative Bioavailability of Mepolizumab 100 mg Liquid Formulation Administered Subcutaneously to Healthy Participants: A Randomized Trial.

Journal: Clinical pharmacology in drug development

Published: April 10, 2019

Reply.

Reply.

Journal: The Journal of allergy and clinical immunology

Published: March 27, 2019

Subcutaneous mepolizumab in children aged 6 to 11 years with severe eosinophilic asthma.

Subcutaneous mepolizumab in children aged 6 to 11 years with severe eosinophilic asthma.

Journal: Pediatric pulmonology

Published: December 21, 2018

Showing 1-12 of 20

Last Updated: 09/26/2026